MOTS-c

MOTS-c was discovered by Pinchas Cohen's laboratory at USC in 2015 as a peptide encoded not in the nuclear genome but within mitochondrial DNA — making it one of a new class of "mitochondria-derived peptides" (MDPs) that have only recently been characterized. This novel origin distinguishes it from all other research peptides and adds a layer of scientific novelty that continues to drive research interest. The compound activates AMPK (AMP-activated protein kinase), the cellular energy sensor often called the "master regulator of metabolism." AMPK activation improves insulin sensitivity, promotes glucose uptake, stimulates fat oxidation, and mimics the metabolic effects of exercise at the cellular level. This "exercise mimetic" characterization has made MOTS-c one of the most scientifically interesting longevity compounds in the current research landscape. In animal studies, MOTS-c has demonstrated improved insulin sensitivity, prevented obesity-related metabolic dysfunction, and extended lifespan in aged mice. It appears to function as a retrograde signal from mitochondria to the nucleus and to other organs — communicating mitochondrial stress and coordinating metabolic adaptation accordingly.

Insulin sensitivity improvement is MOTS-c's most robustly demonstrated metabolic effect in animal models. AMPK activation increases GLUT4 translocation and improves glucose uptake independent of insulin signaling, making MOTS-c particularly interesting for metabolic syndrome, prediabetes, and type 2 diabetes contexts. Exercise mimetic activity — producing some of the metabolic adaptations of exercise without the mechanical work — is the characterization that has attracted the most public attention. While this description is an oversimplification, the AMPK activation and mitochondrial biogenesis effects do mirror aspects of what happens during aerobic exercise at the cellular level. Anti-aging at the mitochondrial level is another well-documented axis of MOTS-c activity. Mitochondrial function declines with aging; MOTS-c appears to support mitochondrial health and metabolic flexibility, which are themselves markers and drivers of biological aging. Lifespan extension in aged mouse models has been published — mice treated with MOTS-c showed extended lifespan and improved healthspan metrics, including better muscle function and metabolic flexibility in late life.

MOTS-c has a favorable safety profile in animal studies and limited human data. No significant adverse effects have been documented in published research. Transient fatigue or energy fluctuation has been reported in some anecdotal human accounts, possibly related to the metabolic shifts driven by AMPK activation. Injection site reactions are the most documented adverse effect in human use — standard mild redness or swelling from SubQ injection. The primary uncertainty is the implications of chronic MOTS-c use on metabolic signaling. AMPK activation, while generally beneficial, interacts with mTOR (the growth signaling pathway) and long-term continuous activation of AMPK could theoretically blunt anabolic signaling in muscle. This is speculative given the limited long-term human data.

Published animal study doses cannot be directly translated to humans. Based on anecdotal human use in the research community, common protocols are: 5–10 mg per week, typically divided into 2–3 injections (e.g., 2.5–3.5 mg three times per week). This is an estimate from the community — no established human dose-response has been published. The injection route (SubQ or IM) is the standard given uncertain oral bioavailability for a peptide of this size and complexity. Given the entirely experimental nature of human dosing, starting at the lower end of any proposed range and monitoring response carefully is appropriate.

MOTS-c is a research chemical with no regulatory approvals in any jurisdiction for human use. It is not a controlled substance. WADA does not currently test for it. Given its very recent discovery and limited research base, regulatory frameworks have not yet specifically addressed it.

MOTS-c + Humanin: Another mitochondria-derived peptide that works through complementary signaling. Humanin primarily activates neuroprotective and insulin sensitizing pathways; MOTS-c activates AMPK-mediated metabolic flexibility. This "mitochondrial peptide stack" represents one of the most forward-looking longevity protocols. MOTS-c + Berberine: Both activate AMPK through different mechanisms. The combination may produce additive AMPK activation, though the implications of very potent AMPK agonism need consideration. MOTS-c + resistance training: Combining the exercise-mimetic metabolic effects of MOTS-c with actual resistance training may produce synergistic outcomes, though this has not been studied.

MOTS-c — Common Questions